Matthew Ferguson
Director of Finance/CFO bei ELUTIA INC.
Vermögen: 382 029 $ am 31.03.2024
Profil
Matthew B.
Ferguson is currently the Chief Financial Officer at Elutia, Inc. He previously worked as a Finance Director at ChannelPoint, Inc. from 1998 to 2002, as the Chief Financial & Accounting Officer at FoxHollow Technologies, Inc. from 2002 to 2007, as the Chief Financial Officer at Tethys Bioscience, Inc. in 2009, as the Chief Financial Officer at Proteolix, Inc. from 2008 to 2009, as the Chief Financial Officer at Bossa Nova Robotics, Inc. from 2018 to 2020, and as the Co-President, Chief Financial & Business Officer at Avinger, Inc. from 2011 to 2018.
He holds an undergraduate degree from Stanford University, a graduate degree from the University of Pennsylvania, and an MBA from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ELUTIA INC CLASS A
0,61% | 08.03.2024 | 121 279 ( 0,61% ) | 382 029 $ | 31.03.2024 |
Aktive Positionen von Matthew Ferguson
Unternehmen | Position | Beginn |
---|---|---|
ELUTIA INC. | Director of Finance/CFO | 28.09.2020 |
Ehemalige bekannte Positionen von Matthew Ferguson
Unternehmen | Position | Ende |
---|---|---|
Bossa Nova Robotics, Inc.
Bossa Nova Robotics, Inc. Recreational ProductsConsumer Durables Bossa Nova Robotics, Inc. designs and manufactures robotic toys. The company was founded by Sarjounin Skaff and David Palmer in Febrauary 2005 and is headquartered in Pittsburgh, PA. | Director of Finance/CFO | 01.07.2020 |
AVINGER, INC. | Director of Finance/CFO | 01.08.2018 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Director of Finance/CFO | 01.12.2010 |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Director of Finance/CFO | 01.04.2009 |
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | Director of Finance/CFO | 01.12.2007 |
Ausbildung von Matthew Ferguson
Stanford University | Undergraduate Degree |
University of Pennsylvania | Graduate Degree |
University of California, Berkeley | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
HP INC. | Electronic Technology |
AVINGER, INC. | Health Technology |
ELUTIA INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
ChannelPoint, Inc.
ChannelPoint, Inc. Insurance Brokers/ServicesFinance ChannelPoint, Inc. provides insurance services over the Internet. It also provides Internet based e-commerce solutions to the insurance industry. The company was founded in December, 1996 by Kenneth E. Hollen and is headquartered in Westminster, CO. | Finance |
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | Health Technology |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Bossa Nova Robotics, Inc.
Bossa Nova Robotics, Inc. Recreational ProductsConsumer Durables Bossa Nova Robotics, Inc. designs and manufactures robotic toys. The company was founded by Sarjounin Skaff and David Palmer in Febrauary 2005 and is headquartered in Pittsburgh, PA. | Consumer Durables |